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Double Stenting for Malignant Biliary and Duodenal
Obstruction: A Systematic Review and Meta-Analysis
Anna Fa´bia´n, MD1, Rena´ta Bor, MD1, Noe´mi Gede, MSc2, Pe´ter Bacsur1, Da´niel Pe´csi, MD2, Pe´ter Hegyi, MD, PhD, DSc2,
Barbara To´th, MPharm, PhD3, Zsolt Szaka´cs, MD2, A´ron Vincze, MD, PhD4, Istva´n Ruzsics, MD5, Zolta´n Rakonczay Jr, MD, PhD, DSc6,
Ba´lint Er}oss, MD2, Ro´bert Sepp, MD, PhD, DSc7 and Zolta´n Szepes, MD, PhD1
INTRODUCTION: Data about the efficacy of palliative double stenting for malignant duodenal and biliary obstruction are
limited.
METHODS: A systematic literature search was performed to assess the feasibility and optimal method of double
stenting for malignant duodenobiliary obstruction compared with surgical double bypass in terms of
technical and clinical success, adverse events, reinterventions, and survival. Event rates with 95%
confidence intervals were calculated.
RESULTS: Seventy-two retrospective and 8 prospective studies published until July 2018 were included.
Technical and clinical success rates of double stenting were 97% (95%–99%) and 92% (89%–95%),
respectively. Clinical success of endoscopic biliary stenting was higher than that of surgery (97%
[94%–99%] vs 86% [78%–92%]). Double stenting was associated with less adverse events (13%
[8%–19%] vs 28% [19%–38%]) but more frequent need for reintervention (21% [16%–27%] vs 10%
[4%–19%]) than double bypass. No significant difference was found between technical and clinical
success and reintervention rate of endoscopic retrograde cholangiopancreatography (ERCP),
percutaneous transhepatic drainage, and endoscopic ultrasound-guided biliary drainage. ERCP was
associated with the least adverse events (3% [1%–6%]), followed by percutaneous transhepatic
drainage (10% [0%–37%]) and endoscopic ultrasound-guided biliary drainage (23% [15%–33%]).
DISCUSSION: Substantially high technical and clinical success can be achieved with double stenting. Based on the
adverse event profile, ERCP can be recommended as the first choice for biliary stenting as part of double
stenting, if feasible.Prospective comparative studieswithwell-definedoutcomesandcohorts areneeded.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A243, http://links.lww.com/CTG/A244, http://links.lww.com/CTG/A245, http://
links.lww.com/CTG/A246, http://links.lww.com/CTG/A247, http://links.lww.com/CTG/A248, http://links.lww.com/CTG/A249, http://links.lww.com/CTG/A250, http://
links.lww.com/CTG/A251
Clinical and Translational Gastroenterology 2020;11:e00161. https://doi.org/10.14309/ctg.0000000000000161
INTRODUCTION
Unresectable pancreatobiliary, gastroduodenal, and metastatic
malignancies can lead to concomitant biliary and duodenal ob-
struction. Biliary obstructionmay occur in 51%–72%of advanced
pancreatobiliary cancers (1,2), and duodenal obstruction rate has
also risen to 38%because of oncologic advances and consequently
longer patient survival (3).
Historically applied double surgical bypass (gastroenterostomy
with biliodigestive anastomosis) (4) is often associated with sub-
stantial perioperative mortality and morbidity (2) because of poor
performance status and frequent comorbidities (5). Because duo-
denal obstruction usually develops after biliary obstruction and it
may occur in up to 20% of those who underwent single biliary
bypass, creation of prophylactic gastroenteric anastomosis (GEA)
was proposed in patients with unresectable disease confirmed at
surgical exploration (2,6). Prophylactic GEA use reduces the
chance for developing duodenal obstructionwithout impairing the
short-termoutcomes in pancreatic and periampullary cancer (6,7).
Therefore, most studies reporting double bypass involve cases
where biliary bypass was combinedwith prophylactic GEA (8–10).
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Endoscopic placement of plastic or self-expandable metal stents
has offered a minimal invasive palliation alternative for patients
unsuitable for surgery. Currently, transpapillary stenting via en-
doscopic retrograde cholangiopancreatography (ERCP) is the
standard treatment of malignant biliary obstruction alone (11,12).
In the case of ERCP failure (reported in approximately 10%because
of altered anatomy or duodenal obstruction), biliary stenting can be
performed via percutaneous transhepatic drainage (PTD) or en-
doscopic ultrasound-guided biliary drainage (EUS-BD) (13). Re-
cently, the first-line use of EUS-BD inmalignant biliary obstruction
was also proposed based on comparable technical and clinical
success and favorable adverse event and reintervention rates over
ERCP (14). In 2018, a Cochrane Database Systematic Review
comparing stent placement and surgical palliation for malignant
gastric outlet obstruction found quicker resumption of oral intake
and reduced hospital stay as benefits and higher reintervention rate
as a drawback of duodenal stenting over surgery (15).
Combined biliary and duodenal stent placement (double
stenting) was first reported in 1994 (16). Adequate modality for
double stenting should be chosen based on duodenal obstruction
type (located above [type I], at the level [type II], or below the
ampulla [type III]) and sequence of biliary and duodenal stenting
(biliary first, duodenal first, or simultaneous). Although techni-
cally challenging, biliary stenting can also be performed through
the mesh of a duodenal stent (11). Nevertheless, the efficacy data
of double stenting are limited, as usually there are few such cases
in a single center (17), partly because of the sequential de-
velopment of biliary and duodenal obstruction, and its place in
the therapeutic algorithm is not clearly specified.
AIMS
This systematic review and meta-analysis aimed to assess efficiency
and safety of double stenting in malignant duodenobiliary ob-
struction comparedwith surgical double bypass in termsof technical
and clinical success, survival, adverse events, and reintervention rate
and determine the optimal method for double stenting: duodenal
stenting combined with ERCP vs PTD vs EUS-BD.
METHODS
Protocol and registration
This work was reported according to the Preferred Reporting
Items for Systematic Reviews andMeta-Analyses 2009 Statement
(18). The study protocol was registered at the International
Prospective Register of Systematic Reviews (PROSPERO) with
the registration number CRD42018103101.
Eligibility criteria
We included studies reporting the following outcome measures in
patients with concomitant malignant biliary and duodenal ob-
struction treated either with combined duodenal and biliary
stenting (via ERCP, PTD, or EUS-BD) or with double surgical
bypass (gastroenterostomy with biliodigestive anastomosis): tech-
nical and clinical success, survival, adverse events, and reinter-
vention rates. Studies reporting about temporary stenting were
excluded. Studies reporting about prophylactic GEA were in-
cluded; however, technical and clinical success could only be
interpreted as that of biliary bypass in such cases.
Both experimental and observational studies (either pro-
spective or retrospective) without respect to their primary
objectives were included. Conference abstracts were included to
minimize publication bias. Case reports and case series reporting
about less than 5 patients were excluded from quantitative
analysis. Eligible articles werewritten in English or had an English
abstract (data were obtained from the abstract in such cases).
Information sources and search strategy
A systematic literature search limited to human studies without
language filters was performed by 2 reviewers in the PubMed
(MEDLINE), EMBASE, Web of Science, and Cochrane Central
Register of Controlled Trials (CENTRAL) databases with the
terms “([biliary obstruction AND duodenal obstruction] OR
bilio-duodenal obstruction) AND (stent OR surgery).” The final
searchwas performed on July 17, 2018. Reference lists of included
articles were also investigated to capture all relevant studies.
Study selection and data collection process
After the removal of duplicates, the following data were extracted
by 2 independent authors: age, gender, type of underlying ma-
lignancy, type of duodenal obstruction, method of biliary drain-
age, type of biliary and duodenal stents, timing of stent placement,
technical and clinical success, adverse events, reintervention rate,
survival, and follow-up.
Risk of bias assessment
Risk of bias was assessed using a modified version of the
Newcastle–Ottawa Scale (NOS) by 2 independent review authors.
Disagreements were resolved by discussion, with involvement of
a third review author, when needed.
The modified NOS contained 7 items covering 2 main
domains (selection and outcome) as comparability domain was
not applicable because of the lack of head-to-head comparative
studies: representativeness of the exposed cohort, selection of the
nonexposed cohort, ascertainment of exposure, demonstration
that the outcome of interest was not present at the study’s start
(selection domain), assessment of outcome, and length and ad-
equacy of follow-up (outcome domain). Studies could be awarded
amaximumof one star for each item. Each itemwas rated as “high
risk” (zero stars) or “low risk” (one star).
Data synthesis and statistical methods
Pooled event rate was calculated for events, and pooled mean was
calculated for continuous datawith 95% confidence intervals (CIs).
A random-effect model was applied in all analyses with the
DerSimonian–Laird estimation. Statistical heterogeneity was ana-
lyzed using the I2 and x2 tests to gain probability values; P, 0.10
was defined to indicate significant heterogeneity. The I2 test rep-
resents the percentage of total variability across studies because of
heterogeneity. I2 values of 30%–60%, 50%–90%, and 75%–100%
corresponded to moderate, substantial, and considerable hetero-
geneity, respectively, based on Cochrane’s handbook (19). Statis-
tical analyses were performed with Comprehensive Meta-Analysis
Software and STATA. Forest plots displayed the results of the
meta-analysis.
Outcome measures
Overall technical success was defined as adequate placement of
both biliary and duodenal stents or successful performance of
double bypass in the case of manifest gastric outlet and biliary
obstruction (4,20,21). Clinical success of biliary stenting was usu-
ally defined as a postprocedural reduction in serum bilirubin level
within 2 weeks. However, this definition varied remarkably across
studies: One study required normalization of serum bilirubin level
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(22), whereas others considered clinical successwhen a 25%or 50%
reduction in bilirubin was observed (17,21,23) or only stated im-
provement of biliary obstruction symptoms without further clari-
fication (4,24). Clinical success of duodenal stenting, when clarified
other than clinical improvement of symptoms (4,24), mainly re-
ferred to a better score on the gastric outlet obstruction scoring
system (21,23). Technical and clinical success was determined for
that of biliary stenting/bypass and duodenal stenting/bypass to-
gether and separately as well.
Cases of prophylactic GEA were also included in the meta-
analysis because it is recommended and commonly applied in the
surgical treatment of pancreatic tumors. However, when pro-
phylactic GEA was included in the surgical group, technical and
clinical success could only be interpreted as that of biliary bypass,
and accordingly, this was compared with technical and clinical
success of biliary stenting.
Survival was determined as the time to death from both stents’
placement (or creation of double bypass). For sequential biliary and
duodenal stenting, survival was calculated from placement of the
later stent. The following adverse events were investigated: pan-
creatitis, cholangitis, cholecystitis, bleeding, bile leakage, perfora-
tion, pneumoperitoneum, abdominal pain, wound infection,
pneumonia, and others (including symptomless amylasemia, atrial
fibrillation, cardiac arrest, aspiration, intra-abdominal abscess, and
deep vein thrombosis). Stent migration, recurrent biliary
obstruction (RBO; defined mostly as per the Tokyo criteria (25)),
and recurrent duodenal obstruction (RDO; reoccurrence of gastric
outlet obstruction symptoms) were also investigated. Adverse event
rate was given as the number of patients with one or more adverse
events. Reintervention rate was defined as the number of patients
who required endoscopic or surgical intervention to treat RBO
or RDO.
RESULTS
Study selection and characteristics
A total of 2,765 records were identified through a database search:
833 in PubMed, 1,531 inEMBASE, 382 inWebof Science, and 19 in
CENTRAL. Nine additional records were found from the reference
list of relevant articles. After removing duplicates and irrelevant
records, 121 studies were found eligible. From these, 41 case reports
and case serieswere excluded fromquantitative synthesis (Figure 1).
Therefore, 80 studies were included in the pooled analysis: 8 pro-
spective and 72 retrospective observational studies (Tables 1 and 2).
No randomized controlled trials were available. Fifty-five studies
including 5,026 patients reported about double stenting, 22 with
1,080 patients about double bypass, and only 3 about both the
techniques (including 64 patients who underwent double stenting
and 93 with double bypass) (8,22,26). However, insufficient out-
come reporting hindered the direct comparison of outcomes.
Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart.
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Table 1. (continued)
Endoscopic
Study Design
No.
Centers
No.
patients
Age (yr)
Sex (female
% of total)
Duodenum
obstruction
Type of
malignancy
Biliary stenting Type of
biliary
stent
Type of
duodenum
stent
Timing Follow-up (d)
Mean Median SD Range
Type
I
Type
II
Type
III ERCP
EUS-
BD PTD
Biliary
first Simultaneous
Duodenal
first Mean Median SD IQR Range
Ogura et al. (68) Retrospective 1 39 70.3 — 9 — 46 28 11 Pancreatobiliary, other 0 39 0 SEMS uSEMS 0 0 39 NA
Paik et al. (69)
(abstract)
Retrospective 1 43 NA NA NA Pancreatic, duodenal, bile duct,
gallbladder, metastatic, other
11 0 32 NA NA 0 0 43 NA
Sato et al. (24) Retrospective 1 43 65.4 — 9.8 — 49 12 18 13 Pancreatic, duodenal, gastric, bile
duct
26 17 0 SEMS uSEMS NA 90 — — — —
Yao et al. (70)
(abstract)
Retrospective 1 42 NA NA NA NA 42 0 0 NA NA 0 0 42 NA
Zhao et al. (71) Retrospective 1 20 63.1 — 8.2 35–72 35 NA Pancreatic, duodenal, bile duct,
metastatic
0 0 20 NA NA 16 1 3 NA
Bulut et al. (72)
(abstract)
Retrospective 1 21 58.7 — 15 — 38 NA Pancreatic, duodenal, ampullary,
gastric, bile duct, metastatic, other
0 0 21 NA uSEMS 14 7 0 112.6 — 152 — —
Fukushima et al.
(73) (abstract)
Retrospective 1 15 NA NA 7 5 3 NA NA NA NA NA NA
Brewer Gutierrez
et al. (74)
Retrospective 3 7 64.7 — 12.5 — 57 NA Pancreatic 0 7 0 SEMS LAMS 0 7 0 — 106 — 66–235 —
Kim et al. (75) Retrospective 1 58 61.1 — 12 — 38 NA Pancreatic, duodenal, gastric, bile
duct, gallbladder, metastatic
58 0 0 SEMS cSEMS 58 0 0 NA
Lee et al. (76) Retrospective 1 12 67.5 — — 38–82 50 4 3 5 Pancreatic, ampullary, bile duct,
gallbladder
11 0 1 SEMS uSEMS 6 6 NA
Matsumoto et al.
(21)
Retrospective 1 81 — 66 — 41–91 40 38 32 11 Pancreatic, ampullary, gastric, bile
duct, gallbladder, metastatic
62 19 0 PS, SEMS cSEMS,
uSEMS
50 31 0 NA
Hamada et al. (17) Retrospective 16 110 68.8 — 11.5 — 52 45 46 19 Pancreatic, ampullary, gastric, bile
duct, gallbladder, other
90 20 0 PS, SEMS NA 67 29 14 NA
Hori et al. (4) Retrospective 8 109 — 70 — 39–96 44 23 74 12 Pancreatobiliary, gastric, other 101 0 8 SEMS cSEMS,
uSEMS
88 12 9 NA
Rai et al. (77)
(abstract)
Prospective 1 12 NA 67 NA NA 7 5 0 SEMS NA NA NA
Staub et al. (20) Retrospective 2 71 66.87 — — 31–92 38 46 21 4 Pancreatic, duodenal, ampullary,
other
71 0 0 PS, SEMS NA 71 NA
Yamao et al. (78) Retrospective 5 39 68.5 — 11.3 — 41 11 16 12 Pancreatic 25 14 0 PS, SEMS NA 9 30 NA
cSEMS, covered self-expandable metallic stent; ERCP, endoscopic retrograde cholangiopancreatography; EUS-BD, endoscopic ultrasound-guided biliary drainage; IQR, interquartile range; LAMS, lumen-apposing metallic stent;
NA, not available; PS, plastic stent; PTD, percutaneous transhepatic drainage; SEMS, self-expandable metallic stent; uSEMS, uncovered self-expandable metallic stent.
aEUS-BD and/or PTD was performed in case of ERCP failure.
bThirteen patients underwent successful biliary cannulation with ERCP, but stent was inserted only in 11 patients.
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Table 2. Characteristics of included studies dealing with surgical double bypass
Surgical
Study Design
No.
Centers
No.
patients
Age Sex (female % of
total) Type of malignancy
Prophylactic
GEA
Follow-up (d)
Mean Median SD IQR Range Mean Median SD Range
Levi et al. (79) Retrospective 1 18 NA NA Pancreatic NA NA
Wongsuwanporn and Basse (80)
(abstract)
Retrospective 1 26 NA NA Pancreatic NA NA
Lee (81) Retrospective 1 65 NA NA Pancreatic, ampullary NA NA
Parker and Postlethwaite (82) Retrospective 1 13 59 — 11 — — 0.5 Pancreatic NA NA
La Ferla and Murray (83) Retrospective 1 14 65 — — — 45–92 36 Pancreatic 14 NA
Singh et al. (84) Retrospective 1 70 63 — — — 12–88 46 Pancreatic 20 NA
Casaccia et al. (85) Prospective 1 2 — 64 — — 53–72 33 Pancreatic 0 12.5 — — 7–18
Hamade et al. (86) Retrospective 1 8 — 70 — — 26–81 43 Pancreatic, duodenal, bile duct 5 NA
Hao et al. (87) Retrospective 1 22 63 — — — 52–76 NA Pancreatic, ampullary, bile duct, duodenal 22 NA
Khan et al. (88) Retrospective 1 2 77 — — — 63–90 53 Pancreatic, duodenal, gastric, bile duct 0 NA
Mortenson et al. (89) Retrospective 1 38 61 — 11 — — NA NA NA NA
Tang et al. (90) (abstract) Retrospective 1 35 — 69 — — — 62 NA NA NA
Ghanem et al. (91) Prospective 1 8 — 67 — — 26–81 59 Pancreatic 3 NA
Lesurtel et al. (27) Retrospective 1 83 64 — 11 — — 46 Pancreatic 72 270 — 270 —
Mann et al. (92) Retrospective 1 102 — 65 — — 36–86 39 Pancreatic, duodenal, ampullary, bile duct,
metastatic
92 NA
Ausania et al. (93) Prospective 1 50 — 64 — — 39–79 34 Pancreatic, duodenal, ampullary, bile duct,
other
50 — 300 — 120–990
Lyons et al. (10) Retrospective 1 60 65 — — — — 45 Pancreatic 50 NA
Malde et al. (94) (abstract) Retrospective 1 48 — — — — — 40 Pancreatic NA NA
Valeshabad et al. (26) (abstract) Retrospective 6 3a 65.9 — — — — 49 NA 0 NA
Bartlett et al. (5) Retrospective 315 351 66 — — 59–75 — 45 Pancreatic NA NA
Kohan et al. (9) Prospective 1 42 64 — — — 38–88 56 Pancreatic 28 NA
Kofokotsios et al. (95) Retrospective 1 11 — 70 — — 48–77 36 Pancreatic 11 NA
Williamson et al. (8) Retrospective 2 59 — 66 — — 39–81 NA Pancreatic, duodenal, ampullary, bile duct,
other
59 NA
Fu et al. (22) Retrospective 1 31 61 — 9.4 — — NA Pancreatic 31 NA
Giuliani and Bonetti (96) (abstract) Retrospective 1 12 — 67 — — 41–83 42 Pancreatic 0 — 323 — 30–3,296
GEA, gastroenteric anastomosis; IQR, interquartile range; NA, not available.
aSurgery was performed in case of ERCP failure.
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Underlying malignancy was specified in 73% of cases: pan-
creatobiliary cancer in 4,149, gastroduodenal cancer in 212,
metastatic cancer in 49, and other malignancies in 144 cases.
Duodenal stenosis was located above and at the ampullary level
in 43.7% each and below the ampulla in 12.5% of reported cases.
Seventeen studies reported about prophylactic GEA, and it was
applied in 69% of surgical cases. In case of double stenting,
biliary stenting was performed via ERCP in 69%, PTD in 17%,
and EUS-BD in 14% of patients. Biliary and duodenal stents
were placed simultaneously in 25.5% of reported cases; biliary
stenting preceded duodenal in 45.7% and followed it in 28.8%.
Themean interval between stent placements was 1146 106 days
(2016 173 days for biliary first and 746 75 days for duodenal
first).
In post hoc analysis, the mean age of patients who underwent
double stenting was significantly higher (67.9 years [95% CI:
67.0–68.9 years; I25 88.0%]) than that of those who underwent
double bypass (63.7 years [95% CI: 62.3–65.0 years; I2 5
89.2%]). Gender distribution showed no difference between the
groups.
Risk of bias assessment
Risk of bias of individual studies was assessed with the NOS (see
Table, Supplementary Digital Content 1, http://links.lww.com/
CTG/A243). Baseline characteristics were reported in almost all
journal articles but were only partially available in conference
abstracts (Tables 1 and 2). Clinical success rate’s definition varied,
and other outcome measures were defined mostly uniformly
(4,17,21–24). Although assessment of different outcomes was
reported reliably in more than 90% (Figure 2), outcomes were
reported heterogeneously (see Tables, Supplementary Digital
Content 2 and 3, http://links.lww.com/CTG/A244 andhttp://links.
lww.com/CTG/A245). Adequate follow-up data were available in
only approximately 40%, but the length of follow-up was appro-
priate for assessment of outcomes, when reported (Figure 2).
Meta-analytical calculations
Technical and clinical success. Overall technical and clinical
success rates of double stenting were 97% (95% CI: 95%–99%)
and 92% (95% CI: 89%–95%), respectively. Subgroup analysis of
different biliary stenting modalities found no difference in
Figure 2. Risk of bias assessment of individual studies according to the modified Newcastle–Ottawa Scale. (a) Endoscopic studies and (b) surgical
studies. Each item was rated as “high risk” (zero stars) or “low risk” (one star). Selection domain: (i) representativeness of the exposed cohort, (ii)
selection of the nonexposed cohort, (iii) ascertainment of exposure, and (iv) demonstration that the outcome of interest was not present at the start of
study. Outcome domain: (v) assessment of outcome, (vi) length of follow-up, and (vii) adequacy of follow-up.
Clinical and Translational Gastroenterology VOLUME 11 | APRIL 2020 www.clintranslgastro.com
R
EV
IE
W
A
R
TI
C
LE
Fa´bia´n et al.8
technical and clinical success (see Figures, Supplementary Digital
Content 4 and 5, http://links.lww.com/CTG/A246 and http://
links.lww.com/CTG/A247).
Considering frequent prophylactic GEA use during surgical
double bypass, technical and clinical success in this group could
only be assessed for biliary bypass. No difference was found be-
tween technical success of endoscopic stenting and surgical biliary
bypass (see Figure, Supplementary Digital Content 6, http://links.
lww.com/CTG/A248), whereas clinical success of endoscopic bil-
iary stenting was higher (97% [95% CI: 94%–99%; I25 67.3%] vs
86% [95% CI: 78%–92%; I2 5 19.9%], respectively) (Figure 3).
Technical and clinical success of duodenal stenting was 99% (95%
CI: 97%–100%) and 97% (95% CI: 94%–99%), respectively.
Adverse event rate. Double stenting was associated with less ad-
verse events compared with surgical double bypass (13% [95% CI:
8%–19%; I2 5 86.3%] vs 28% [95% CI: 19%–38%; I2 5 89.3%])
(Figure 4). See Table (Supplementary Digital Content 7, http://
links.lww.com/CTG/A249) for details of adverse events associated
with double stenting and double bypass. Adverse events occurred
at 67.8 days on average (95% CI: 5.1–128.4 days) postprocedure.
There was no difference between adverse events’ occurrence time
after double stenting and double bypass (52.8 days [95% CI:
23.7–129.3 days] vs 108.7 days [95% CI: 123.2–340.6 days],
respectively).
ERCPwas associatedwith the least adverse events (3% [95%CI:
1%–6%; I2 5 42.8%]), followed by PTD (10% [95% CI: 0%–37%;
Figure 3. Clinical success of biliary bypass in case of double stenting and double surgical bypass (including cases with prophylactic GEA). CI, confidence
interval; ES, effect size; GEA, gastroenteric anastomosis.
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Figure 4. Adverse events related to double stenting and double surgical bypass. CI, confidence interval; ES, effect size.
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I2 5 90.2%]) and EUS-BD (23% [95% CI: 15%–33%; I2 5 1.8%])
(Figure 5). The difference was significant between ERCP and
EUS-BD.
Reintervention rate. More reinterventions were needed after
double stenting than after double bypass (21% [95% CI:
16%–27%; I2 5 79.4%] vs 10% [95% CI: 4%–19%; I2 5 90.2%])
(see Figure, Supplementary Digital Content 8, http://links.lww.
com/CTG/A250). In subgroup analysis, reinterventions were
least likely to be necessary after PTD (4% [95% CI: 0%–15%]),
followed by ERCP and EUS-BD (16% [95% CI: 9%–24%] and
32% [95% CI: 15%–50%], respectively) (Figure 6).
Although only 2 surgical studies specified whether reinterven-
tion was necessary because of RBO or RDO (26,27), several en-
doscopic studies investigated RBO and RDO separately (see Table,
Supplementary Digital Content 2, http://links.lww.com/CTG/
A244). RBOwas reported in a total of 285 cases, whereas RDOwas
reported in 100 cases. The mean time until the occurrence of RBO
and RDO was 167.3 days (95% CI: 93.0–241.6 days; I2 5 96.0%)
and 106.0 days (95%CI: 56.7–155.3 days; I25 51.1%), respectively.
Survival. Cumulative mean survival of patients after double
stenting was 156.4 days (95% CI: 128.3–184.5 days). Subgroup
analysis of the different biliary stentingmethods as part of double
stenting revealed no difference in mean survival (see Figure,
Supplementary Digital Content 9, http://links.lww.com/CTG/
A251). A small number of surgical studies and frequent GEA use
in the surgical cohort prevented comparison of survival in the
endoscopic and surgical cohorts.
DISCUSSION
Although double stenting for combined malignant biliary and du-
odenal obstruction has been a treatment option for 25 years (16), its
place in the therapeutic algorithmhasnot been clearly specified, and
reliable efficacy data are still lacking because of the rare concomitant
occurrence of these conditions (17). To the best of our knowledge,
Figure 5. Adverse events related to ERCP, EUS-BD, and PTD. CI, confidence interval; ERCP, endoscopic retrograde cholangiopancreatography; ES, effect
size; EUS-BD, endoscopic ultrasound-guided biliary drainage; PTD, percutaneous transhepatic drainage.
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this is the first systematic review andmeta-analysis dealing with the
feasibility of double endoscopic stenting in this scenario.
According to our findings, high cumulative technical and
clinical success rates can be achieved with double stenting in this
difficult-to-treat population. Success rates were comparable with
traditionally applied surgical bypass regarding biliary bypass;
moreover, clinical success rate of endoscopic biliary bypass was
even higher than that of surgery. The importance of this finding
lies in the fact that those underwent double stenting were sig-
nificantly older compared with those with double bypass, sug-
gesting a potential superiority of double stenting in the elderly.
The adverse event profile of double stenting was favorable over
that of double bypass in terms of not onlynumbers but also severity
(death was only reported in the surgical cohort). However, the
occurrence of adverse events depends on the method of biliary
stenting: ERCP was associated with significantly fewer adverse
events than EUS-BD. A previous meta-analysis about EUS-BD
reported a similarly high cumulative adverse event rate (23.32%)
(28). The high proportion of ERCPs in the double stenting cohort
may also contribute to the overall adverse event rate.
However, double stenting was associated with higher reinter-
vention rate independently of the biliary stenting method.
Duodenal stent placement alone was found to require more rein-
terventions than surgery (15), and a recentmulticenter randomized
controlled trial comparing ERCP and EUS-BD as the primary
treatment modality of malignant biliary obstruction reported
reintervention rates of 42.6% and 15.6%, respectively (14). These
facts, and plastic biliary stents’ use in numerous studies and in-
clusion of early studies dealing with double stenting, might also
contribute to high reintervention rates (29). Considering cumula-
tive survival and mean time until RBO or RDO, generally one
reintervention will be necessary for patients undergoing double
stenting. Nevertheless, PTD and EUS-BDwere mostly second-line
treatments after ERCP failure, and the exact number of sessions
required to stent placement (especially for PTD, when stenting is
often performed in a second session after temporary external bil-
iary drainage) was generally not reported; therefore, complete
burden of interventions cannot be reliably assessed.
CommonprophylacticGEAuse in double bypass also needs to
be considered. Because it is associated with a lower risk of de-
velopment of duodenal stenosis (6,7), lower rates of reinterven-
tions for RDO are expected in the surgical cohort, which consists
mostly of cases with prophylactic GEA. Therefore, cumulative
overall reintervention rates might also be lower; however, details
Figure 6. Reintervention rate related to ERCP, PTD, and EUS-BD. CI, confidence interval; ERCP, endoscopic retrograde cholangiopancreatography; ES,
effect size; EUS-BD, endoscopic ultrasound-guided biliary drainage; PTD, percutaneous transhepatic drainage.
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of conditions requiring reintervention in this cohort were gen-
erally not reported. Another aspect related to prophylactic GEA
use is the impossibility to compare overall success rates of the
cohorts because technical and clinical success of duodenal bypass
is not applicable in such cases.
Limitations
The main limitation was the lack of head-to-head comparative
studies assessing double stenting and double bypass; therefore,
only an indirect comparison could be provided with significant
heterogeneity between studies. Different timing of biliary and
duodenal interventions and frequent second-line use of PTD and
EUS-BD increase heterogeneity further. Numerous studies were
retrospective or not available as full text, and being a relatively
rare entity, a huge part of literature (particularly for EUS-BD)
consists of case reports and case series.
Results of double stenting and double bypass must be com-
pared with caution because the cohorts may not consist of the
exact same population (double stenting was traditionally an al-
ternative for patients unfit for surgery). The higher age of those
underwent double stenting seems to be confirming this; however,
objective measures to assess operative risk (e.g., the American
Society of Anesthesiologists classification system), which might
serve as a basis for such a distinction, were not reported.
Implications for practice
A crucial clinical question regarding malignant duodenobiliary
obstruction is whether to refer patients to surgery or endoscopy
for palliation. According to ourmeta-analysis, high technical and
clinical success rates, especially the higher clinical success rate of
endoscopic biliary stenting compared with surgical bypass, and
the lower adverse event rate suggest a justification of minimally
invasive techniques in this setting, but high reintervention rates
should also be acknowledged. Based on the adverse event profile,
when technically feasible, ERCP can be recommended as the first-
choice method for biliary stenting also in case of duodenobiliary
stenosis, but high reintervention rates and frequent sequential
development of duodenal stenosis do not allow to make general
recommendations. Caution should be taken because of the lim-
ited and substantially heterogeneous available evidence.
Implications for research
To define the cohorts that can benefit most from double stenting,
there is a pressing need formulticentric, prospective, comparative
studies with well-defined outcomemeasures and carefully chosen
cohorts. Aspects such as prophylactic GEA use, selection of
patients “unfit for surgery” based on the well-defined scoring
systems for risk stratification, and the possible use of EUS-BD as
the primary treatment option should also be considered.
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